Cargando…

Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis?

Down syndrome (DS), or trisomy 21, is the most prevalent chromosomal anomaly accounting for cognitive impairment and intellectual disability (ID). Neuropathological changes of DS brains are characterized by a reduction in the number of neurons and oligodendrocytes, accompanied by hypomyelination and...

Descripción completa

Detalles Bibliográficos
Autores principales: Reiche, Laura, Küry, Patrick, Göttle, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953000/
https://www.ncbi.nlm.nih.gov/pubmed/31817891
http://dx.doi.org/10.3390/cells8121591
_version_ 1783486550113255424
author Reiche, Laura
Küry, Patrick
Göttle, Peter
author_facet Reiche, Laura
Küry, Patrick
Göttle, Peter
author_sort Reiche, Laura
collection PubMed
description Down syndrome (DS), or trisomy 21, is the most prevalent chromosomal anomaly accounting for cognitive impairment and intellectual disability (ID). Neuropathological changes of DS brains are characterized by a reduction in the number of neurons and oligodendrocytes, accompanied by hypomyelination and astrogliosis. Recent studies mainly focused on neuronal development in DS, but underestimated the role of glial cells as pathogenic players. Aberrant or impaired differentiation within the oligodendroglial lineage and altered white matter functionality are thought to contribute to central nervous system (CNS) malformations. Given that white matter, comprised of oligodendrocytes and their myelin sheaths, is vital for higher brain function, gathering knowledge about pathways and modulators challenging oligodendrogenesis and cell lineages within DS is essential. This review article discusses to what degree DS-related effects on oligodendroglial cells have been described and presents collected evidence regarding induced cell-fate switches, thereby resulting in an enhanced generation of astrocytes. Moreover, alterations in white matter formation observed in mouse and human post-mortem brains are described. Finally, the rationale for a better understanding of pathways and modulators responsible for the glial cell imbalance as a possible source for future therapeutic interventions is given based on current experience on pro-oligodendroglial treatment approaches developed for demyelinating diseases, such as multiple sclerosis.
format Online
Article
Text
id pubmed-6953000
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69530002020-01-23 Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis? Reiche, Laura Küry, Patrick Göttle, Peter Cells Review Down syndrome (DS), or trisomy 21, is the most prevalent chromosomal anomaly accounting for cognitive impairment and intellectual disability (ID). Neuropathological changes of DS brains are characterized by a reduction in the number of neurons and oligodendrocytes, accompanied by hypomyelination and astrogliosis. Recent studies mainly focused on neuronal development in DS, but underestimated the role of glial cells as pathogenic players. Aberrant or impaired differentiation within the oligodendroglial lineage and altered white matter functionality are thought to contribute to central nervous system (CNS) malformations. Given that white matter, comprised of oligodendrocytes and their myelin sheaths, is vital for higher brain function, gathering knowledge about pathways and modulators challenging oligodendrogenesis and cell lineages within DS is essential. This review article discusses to what degree DS-related effects on oligodendroglial cells have been described and presents collected evidence regarding induced cell-fate switches, thereby resulting in an enhanced generation of astrocytes. Moreover, alterations in white matter formation observed in mouse and human post-mortem brains are described. Finally, the rationale for a better understanding of pathways and modulators responsible for the glial cell imbalance as a possible source for future therapeutic interventions is given based on current experience on pro-oligodendroglial treatment approaches developed for demyelinating diseases, such as multiple sclerosis. MDPI 2019-12-07 /pmc/articles/PMC6953000/ /pubmed/31817891 http://dx.doi.org/10.3390/cells8121591 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Reiche, Laura
Küry, Patrick
Göttle, Peter
Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis?
title Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis?
title_full Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis?
title_fullStr Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis?
title_full_unstemmed Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis?
title_short Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis?
title_sort aberrant oligodendrogenesis in down syndrome: shift in gliogenesis?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953000/
https://www.ncbi.nlm.nih.gov/pubmed/31817891
http://dx.doi.org/10.3390/cells8121591
work_keys_str_mv AT reichelaura aberrantoligodendrogenesisindownsyndromeshiftingliogenesis
AT kurypatrick aberrantoligodendrogenesisindownsyndromeshiftingliogenesis
AT gottlepeter aberrantoligodendrogenesisindownsyndromeshiftingliogenesis